NCT02711345View on ClinicalTrials.gov

A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.

PHASE1TerminatedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

April 15, 2016

Primary Completion Date

November 21, 2018

Study Completion Date

November 21, 2018

Conditions
Ovarian NeoplasmsNon-Small-Cell Lung CarcinomaMelanomaOther Solid Tumors
Interventions
DRUG

LTT462

ERK Inhibitor

Trial Locations (7)

6500

Novartis Investigative Site, Bellinzona

10065

Novartis Investigative Site, New York

45147

Novartis Investigative Site, Essen

169610

Novartis Investigative Site, Singapore

77030-4009

Novartis Investigative Site, Houston

104 0045

Novartis Investigative Site, Chuo Ku

08035

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY